{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2014:OYUNQD5N3Q5MVQO7Q4STFE6VA4","short_pith_number":"pith:OYUNQD5N","canonical_record":{"source":{"id":"1410.0762","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-10-03T06:48:20Z","cross_cats_sorted":["stat.AP"],"title_canon_sha256":"f259b68de4a1d507e2b38ad411b98f98a56fc2d76b0342fc87e6affed2402e80","abstract_canon_sha256":"85f0492bb978217fc9e0d1f3072e994680c2d320e5ca4759da87b2b6737431cd"},"schema_version":"1.0"},"canonical_sha256":"7628d80faddc3acac1df87253293d5070113bd496d9af61ac7578118c80e4823","source":{"kind":"arxiv","id":"1410.0762","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1410.0762","created_at":"2026-05-18T02:37:51Z"},{"alias_kind":"arxiv_version","alias_value":"1410.0762v1","created_at":"2026-05-18T02:37:51Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1410.0762","created_at":"2026-05-18T02:37:51Z"},{"alias_kind":"pith_short_12","alias_value":"OYUNQD5N3Q5M","created_at":"2026-05-18T12:28:43Z"},{"alias_kind":"pith_short_16","alias_value":"OYUNQD5N3Q5MVQO7","created_at":"2026-05-18T12:28:43Z"},{"alias_kind":"pith_short_8","alias_value":"OYUNQD5N","created_at":"2026-05-18T12:28:43Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2014:OYUNQD5N3Q5MVQO7Q4STFE6VA4","target":"record","payload":{"canonical_record":{"source":{"id":"1410.0762","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-10-03T06:48:20Z","cross_cats_sorted":["stat.AP"],"title_canon_sha256":"f259b68de4a1d507e2b38ad411b98f98a56fc2d76b0342fc87e6affed2402e80","abstract_canon_sha256":"85f0492bb978217fc9e0d1f3072e994680c2d320e5ca4759da87b2b6737431cd"},"schema_version":"1.0"},"canonical_sha256":"7628d80faddc3acac1df87253293d5070113bd496d9af61ac7578118c80e4823","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T02:37:51.381172Z","signature_b64":"5HQGkZFQ5ds1YF1Sq+ralPnrIfU7ja6wotoc/lleODHxcFMH+kCYlqVbABCjjVD9vBX5tUdZc4YmJ8gGeuLsDQ==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"7628d80faddc3acac1df87253293d5070113bd496d9af61ac7578118c80e4823","last_reissued_at":"2026-05-18T02:37:51.380625Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T02:37:51.380625Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1410.0762","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T02:37:51Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"9iU/wDJltH8ka+O519Y4K1kJOLk43AnV0cwkvfotnddy4tyOLajGAhtN+IqzUEtn3SQbmHbul/n+kNW8NZfeAg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-26T14:26:38.238569Z"},"content_sha256":"a56cc290b24d94039294e9d1b06e7b0b3cebdaca1baec82f0fb2b12afdb0049e","schema_version":"1.0","event_id":"sha256:a56cc290b24d94039294e9d1b06e7b0b3cebdaca1baec82f0fb2b12afdb0049e"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2014:OYUNQD5N3Q5MVQO7Q4STFE6VA4","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["stat.AP"],"primary_cat":"q-bio.QM","authors_text":"Ahmad Amanzada, Christian R\\\"over, Nicolae-Catalin Mechie, Silke Cameron","submitted_at":"2014-10-03T06:48:20Z","abstract_excerpt":"AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-$\\alpha$ (Peg-INF-$\\alpha$) based triple-therapy.\n  METHODS: We searched PubMed, the Cochrane Library and Web of Knowledge for studies regarding the interleukin 28B (IL-28B)-genotype and protease-inhibitor based triple-therapy. Ten studies with 2707 patients were included into this meta-analysis. We used regression methods in o"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1410.0762","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T02:37:51Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"QQsvCcMCSROGv0Et8RD6wRYWIlipidrJHgRAOkIUpSAaVWWBp/gDkosS0d07bwr9Z6l1KJiJINxJR/RnM5GWBw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-26T14:26:38.239207Z"},"content_sha256":"b787286fadbf1522c877696172cc2b970f6b1563014d3e8b894b55a183ead9c9","schema_version":"1.0","event_id":"sha256:b787286fadbf1522c877696172cc2b970f6b1563014d3e8b894b55a183ead9c9"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/OYUNQD5N3Q5MVQO7Q4STFE6VA4/bundle.json","state_url":"https://pith.science/pith/OYUNQD5N3Q5MVQO7Q4STFE6VA4/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/OYUNQD5N3Q5MVQO7Q4STFE6VA4/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-05-26T14:26:38Z","links":{"resolver":"https://pith.science/pith/OYUNQD5N3Q5MVQO7Q4STFE6VA4","bundle":"https://pith.science/pith/OYUNQD5N3Q5MVQO7Q4STFE6VA4/bundle.json","state":"https://pith.science/pith/OYUNQD5N3Q5MVQO7Q4STFE6VA4/state.json","well_known_bundle":"https://pith.science/.well-known/pith/OYUNQD5N3Q5MVQO7Q4STFE6VA4/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2014:OYUNQD5N3Q5MVQO7Q4STFE6VA4","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"85f0492bb978217fc9e0d1f3072e994680c2d320e5ca4759da87b2b6737431cd","cross_cats_sorted":["stat.AP"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-10-03T06:48:20Z","title_canon_sha256":"f259b68de4a1d507e2b38ad411b98f98a56fc2d76b0342fc87e6affed2402e80"},"schema_version":"1.0","source":{"id":"1410.0762","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1410.0762","created_at":"2026-05-18T02:37:51Z"},{"alias_kind":"arxiv_version","alias_value":"1410.0762v1","created_at":"2026-05-18T02:37:51Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1410.0762","created_at":"2026-05-18T02:37:51Z"},{"alias_kind":"pith_short_12","alias_value":"OYUNQD5N3Q5M","created_at":"2026-05-18T12:28:43Z"},{"alias_kind":"pith_short_16","alias_value":"OYUNQD5N3Q5MVQO7","created_at":"2026-05-18T12:28:43Z"},{"alias_kind":"pith_short_8","alias_value":"OYUNQD5N","created_at":"2026-05-18T12:28:43Z"}],"graph_snapshots":[{"event_id":"sha256:b787286fadbf1522c877696172cc2b970f6b1563014d3e8b894b55a183ead9c9","target":"graph","created_at":"2026-05-18T02:37:51Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-$\\alpha$ (Peg-INF-$\\alpha$) based triple-therapy.\n  METHODS: We searched PubMed, the Cochrane Library and Web of Knowledge for studies regarding the interleukin 28B (IL-28B)-genotype and protease-inhibitor based triple-therapy. Ten studies with 2707 patients were included into this meta-analysis. We used regression methods in o","authors_text":"Ahmad Amanzada, Christian R\\\"over, Nicolae-Catalin Mechie, Silke Cameron","cross_cats":["stat.AP"],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-10-03T06:48:20Z","title":"Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1410.0762","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:a56cc290b24d94039294e9d1b06e7b0b3cebdaca1baec82f0fb2b12afdb0049e","target":"record","created_at":"2026-05-18T02:37:51Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"85f0492bb978217fc9e0d1f3072e994680c2d320e5ca4759da87b2b6737431cd","cross_cats_sorted":["stat.AP"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2014-10-03T06:48:20Z","title_canon_sha256":"f259b68de4a1d507e2b38ad411b98f98a56fc2d76b0342fc87e6affed2402e80"},"schema_version":"1.0","source":{"id":"1410.0762","kind":"arxiv","version":1}},"canonical_sha256":"7628d80faddc3acac1df87253293d5070113bd496d9af61ac7578118c80e4823","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"7628d80faddc3acac1df87253293d5070113bd496d9af61ac7578118c80e4823","first_computed_at":"2026-05-18T02:37:51.380625Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T02:37:51.380625Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"5HQGkZFQ5ds1YF1Sq+ralPnrIfU7ja6wotoc/lleODHxcFMH+kCYlqVbABCjjVD9vBX5tUdZc4YmJ8gGeuLsDQ==","signature_status":"signed_v1","signed_at":"2026-05-18T02:37:51.381172Z","signed_message":"canonical_sha256_bytes"},"source_id":"1410.0762","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:a56cc290b24d94039294e9d1b06e7b0b3cebdaca1baec82f0fb2b12afdb0049e","sha256:b787286fadbf1522c877696172cc2b970f6b1563014d3e8b894b55a183ead9c9"],"state_sha256":"66aed9e46fab97286a9e44b511c3e220727a5d7b6e622b7de2aa1877a99b82dd"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"Iq/kJPPILPDjwrjbYWTvNHmUPGKz+nHBUce0EuSz1f/3dY1dxFsIWuFUYGaU4ywK3uVML0v2gQlZ8q2BLbXSAw==","signed_message":"bundle_sha256_bytes","signed_at":"2026-05-26T14:26:38.242729Z","bundle_sha256":"f80f0a7e5c27f9170cd6c48a6609c1b17ea92cf0974a0e48bae04e58d8fc1ac1"}}